Media

January 05, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces two additions to their Scientific Advisory Board. “We could not

Allergy treatments enter a new era — with a focus on stopping reactions before they start MEGHANA KESHAVAN @megkesh NOVEMBER 29, 2016 Allergy treatments haven’t advanced much in decades, even

April 27-28, 2017 Bethesda Marriott Conference Center Presented by the Maryland Technology Council, Bio+Tech17 reflects the changing landscape where life science and technology converge by bringing together more than 600

ITI announced the issuance of a new United States Patent which extends ITI’s intellectual property portfolio covering their proprietary vectors, including ITI’s out-licensed investigational DNA vaccines. Specifically, U.S. Patent No. 9,499,589

The Washington Business Journal article tells the story of the evolution of Immunomic Therapeutics and its strategy in applying LAMP-Vax in dierent disease areas. The article further highlights Immunomics partnering

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Paragon Bioservices, Inova, University System of Maryland and Medimmune/AstraZeneca. Maryland, Virginia, and Washington,

Please take a look at our very own scientists and executives that were highlighted in BioHive, an online community platform for the Bio health Industry.

ASTELLAS Announces FDA Fast Track Designation for ASP0892 DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions Due to Peanut Allergy NEWS PROVIDED BY Astellas Pharma Inc. Dec 20, 2016, 08:00

February 02, 2017 06:45 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced the finalists for their Cancer Discovery Incubator Award: Alcamena

January 05, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces two additions to their Scientific Advisory Board. “We could not

TOKYO, Dec. 20, 2016 /PRNewswire/ -- Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, "Astellas") and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., "Immunomic Therapeutics") today announced that the

December 14, 2016 07:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces that C. Eric Winzer, M.B.A., currently serving Immunomic as Chief